Inovio Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jacqueline Shea
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 30.8% |
| CEO tenure | 2yrs |
| CEO ownership | 0.08% |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$751k | -US$135m |
| Sep 30 2023 | n/a | n/a | -US$165m |
| Jun 30 2023 | n/a | n/a | -US$168m |
| Mar 31 2023 | n/a | n/a | -US$241m |
| Dec 31 2022 | US$4m | US$730k | -US$280m |
| Sep 30 2022 | n/a | n/a | -US$332m |
| Jun 30 2022 | n/a | n/a | -US$355m |
| Mar 31 2022 | n/a | n/a | -US$328m |
| Dec 31 2021 | US$2m | US$468k | -US$304m |
| Sep 30 2021 | n/a | n/a | -US$221m |
| Jun 30 2021 | n/a | n/a | -US$142m |
| Mar 31 2021 | n/a | n/a | -US$188m |
| Dec 31 2020 | US$2m | US$431k | -US$166m |
| Sep 30 2020 | n/a | n/a | -US$180m |
| Jun 30 2020 | n/a | n/a | -US$222m |
| Mar 31 2020 | n/a | n/a | -US$123m |
| Dec 31 2019 | US$1m | US$335k | -US$119m |
Compensation vs Market: Jacqueline's total compensation ($USD2.44M) is above average for companies of similar size in the German market ($USD993.65K).
Compensation vs Earnings: Jacqueline's compensation has been consistent with company performance over the past year.
CEO
Jacqueline Shea (57 yo)
2yrs
Tenure
US$2,438,908
Compensation
Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2yrs | US$2.44m | 0.079% $ 230.6k | |
| Chief Financial Officer | 21.9yrs | US$1.16m | 0.087% $ 253.3k | |
| Chief Scientific Officer | 5.2yrs | US$1.14m | 0.082% $ 239.1k | |
| Manager of Investor Relations | no data | no data | no data | |
| General Counsel & Chief Compliance Officer | 2.5yrs | no data | no data | |
| Senior Vice President of Quality Assurance | no data | no data | no data | |
| Senior Vice President of Clinical Development | 3.6yrs | no data | no data | |
| Senior Vice President of Biological Manufacturing & Clinical Supply Management | 3.6yrs | no data | no data | |
| Senior Vice President of Engineering Development | no data | no data | no data | |
| Senior Vice President of Business Development | 3.3yrs | no data | no data | |
| Chief Commercial Officer | 3.6yrs | no data | no data | |
| Senior Vice President of Early-Stage Clinical Development | less than a year | no data | no data |
3.6yrs
Average Tenure
57yo
Average Age
Experienced Management: GBM's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2yrs | US$2.44m | 0.079% $ 230.6k | |
| Independent Director | 6.4yrs | US$123.69k | 0.024% $ 69.4k | |
| Independent Director | 5.3yrs | US$118.69k | 0.017% $ 49.4k | |
| Independent Director | 4.3yrs | US$119.31k | 0.019% $ 54.8k | |
| Independent Chairman of Board of Directors | 20.4yrs | US$151.19k | 0.030% $ 88.3k | |
| Chairman of the Scientific Advisory Board & Director | 24.3yrs | US$201.79k | 0.31% $ 903.0k | |
| Member of Scientific Advisory Board | 14.9yrs | no data | no data | |
| Independent Director | 5.2yrs | US$126.94k | 0.021% $ 62.3k | |
| Member of Scientific Advisory Board | 12.2yrs | no data | no data | |
| Independent Director | 3yrs | US$108.69k | 0.014% $ 40.3k | |
| Member of Scientific Advisory Board | 5.5yrs | no data | no data |
5.5yrs
Average Tenure
67yo
Average Age
Experienced Board: GBM's board of directors are considered experienced (5.5 years average tenure).